Part of 3. 3. Topical Questions – in the Senedd at 3:26 pm on 20 September 2017.
Vaughan Gething
Labour
3:26,
20 September 2017
The All Wales Medicines Strategy Group, the AWMSG, has appraised Avastin to treat recurrent or advanced cervical cancer. The AWMSG recommended against its routine use as the evidence for clinical cost-effectiveness was insufficient.
